NeuroMito Therapeutics is a biotechnology company focused on developing next-generation mitochondrial antioxidants for the treatment of Parkinson's disease and related neurodegenerative disorders. Founded in 2018 and headquartered in Boston, Massachusetts, NeuroMito's proprietary mitochondrial-targeted antioxidant platform addresses the oxidative stress component of PD pathogenesis[1].
The company's lead program, NMT-101, is a mitochondria-targeted nitroxide compound designed to selectively scavenge reactive oxygen species (ROS) within mitochondria while preserving essential cellular signaling functions.
Oxidative stress is a central pathological feature in Parkinson's disease:
Previous antioxidant approaches have shown limited efficacy in PD clinical trials:
NMT-101 overcomes these limitations through:
| Drug | Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| NMT-101 | Mitochondrial antioxidant | Parkinson's Disease | Phase 2 | Active |
| NMT-201 | ROS modulator | PD with dementia | Phase 1 | IND-cleared |
| NMT-301 | Mitocholuorophyll | ALS | Discovery | Research |
NMT-101-CL-002 (2024-2025): A 52-week, randomized, double-blind, placebo-controlled Phase 2 trial in patients with early-to-moderate Parkinson's disease[3]:
| Parameter | Value |
|---|---|
| Patients | 180 (60 per arm) |
| Doses | 10mg, 30mg, placebo |
| Duration | 52 weeks |
| Primary endpoint | Change in MDS-UPDRS total score |
| Secondary endpoints | Motor complications, non-motor symptoms, biomarker changes |
Enrollment criteria:
NMT-101 development includes robust biomarker assessment:
In the MPTP mouse model of PD, NMT-101:
In chronic rotenone-exposed rats:
In 18-month-old mice:
| Attribute | Details |
|---|---|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2018 |
| CEO | Dr. Robert W. Harrison |
| CSO | Dr. Linda K. Park |
| Funding | Series A ($18M, 2019), Series B ($40M, 2022), Series C ($65M, 2025) |
| Investors | Atlas Venture, Novartis Venture Fund, Bristol Myers Squibb |
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| NeuroMito | NMT-101 | Mitochondrial antioxidant | Phase 2 |
| Clene | CNM-Au8 | Catalytic antioxidant | Phase 2 |
| Vandria | VNA-100 | Mitochondrial modulator | Preclinical |
| Napa | NP-101 | Mitochondria protectant | Phase 1 |